GLP-1 Receptor Agonists and Platelet Function: Potential Benefits Beyond Glycemic Control
Xanthopoulou M et al.
Summary
This review synthesizes preclinical and clinical evidence showing that GLP-1 RAs may reduce platelet activation through both receptor-dependent and independent mechanisms, including cAMP signaling, increased nitric oxide bioavailability, and suppression of thromboxane-mediated pathways. Clinical studies, while limited, support a reduction in platelet activation markers independent of glycemic control or weight loss.
Clinical Significance
The antiplatelet effects of GLP-1 RAs represent an underappreciated mechanism contributing to their cardiovascular benefits beyond glucose lowering. For clinicians managing patients on antiplatelet therapy or with elevated cardiovascular risk, this suggests GLP-1 RAs may offer additive hemostatic modulation—but also warrants caution regarding bleeding risk when combined with other antithrombotic agents.
Investigación Relacionada
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Depression: A Systematic Review and Meta-Analysis
This comprehensive meta-analysis evaluated the association between GLP-1 receptor agonist use and de…
Glucagon-like Peptide-1 Receptor Agonists and Risk of Depression: A Systematic Review and Meta-Analysis
This comprehensive meta-analysis examined the relationship between GLP-1 receptor agonist use and de…
Exposure-Adjusted Safety and Efficacy of GLP-1 and GLP-1/GIP Receptor Agonists for Weight Management and Type 2 Diabetes
This comprehensive analysis of FDA regulatory data across 14 medications and over 34,000 safety subj…
GLP-1 Analogs Activate AMP Kinase Leading to Reversal of the Warburg Effect in Breast Cancer Cells
GLP-1 receptor agonists were shown to activate AMP kinase and reverse the Warburg metabolic switch i…